Therapeutic Strategies Focusing on Immune Dysregulation and Neuroinflammation in Rosacea

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Aug 13

PMID 39136023

Authors

Kuan-Yi Tu

Chiau-Jing Jung

Yi-Hsien Shih

Anne Lynn S Chang

Affiliations

Soon will be listed here.

Abstract

Rosacea is a complex inflammatory condition characterized by papulopustular lesions and erythema on the central face for which there is no cure. The development of rosacea is influenced by both external triggers and genetics, but the common pathophysiology is overactivation of the immune system. Here, we review the current data on proinflammatory cytokines and dysregulation of the neurovascular system as targetable components of rosacea. Amelioration of cutaneous and gastrointestinal dysbiosis and other external factors impacts the immune state and has been observed to improve rosacea. While multiple treatments exist, many patients do not achieve their goals for rosacea control and highlights an unmet need for dermatologic care. Current interventions encompass topical/oral drugs, light devices, and avoidance of triggers management. Additional understanding of the underlying pathogenesis may help us develop novel targeted therapeutic strategies to improve rosacea.

Citing Articles

Managing a Burning Face: Clinical Manifestations and Therapeutic Approaches for Neurogenic Rosacea.

Aedo G, Chahuan M, Gatica E, Herrera I, Parada L, Seguel A Int J Mol Sci. 2025; 26(5).

PMID: 40076987 PMC: 11901027. DOI: 10.3390/ijms26052366.

Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases.

Zhao H, Zhao H, Tang Y, Li M, Cai Y, Xiao X Biomark Res. 2024; 12(1):118.

PMID: 39385245 PMC: 11465885. DOI: 10.1186/s40364-024-00663-0.

References

Schaller M, Almeida L, Bewley A, Cribier B, Dlova N, Kautz G . Rosacea treatment update: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol. 2016; 176(2):465-471. DOI: 10.1111/bjd.15173. View

Clanner-Engelshofen B, Bernhard D, Dargatz S, Flaig M, Gieler U, Kinberger M . S2k guideline: Rosacea. J Dtsch Dermatol Ges. 2022; 20(8):1147-1165. DOI: 10.1111/ddg.14849. View

Kanada K, Nakatsuji T, Gallo R . Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012; 132(5):1435-42. PMC: 4169281. DOI: 10.1038/jid.2012.14. View

Pye R, Burton J . Treatment of rosacea by metronidazole. Lancet. 1976; 1(7971):1211-2. DOI: 10.1016/s0140-6736(76)92160-7. View

Li J, Yuan X, Tang Y, Wang B, Deng Z, Huang Y . Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020; 79:106178. DOI: 10.1016/j.intimp.2019.106178. View

Aponte J, Chiano M, Yerges-Armstrong L, Hinds D, Tian C, Gupta A . Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. Hum Mol Genet. 2018; 27(15):2762-2772. PMC: 6822543. DOI: 10.1093/hmg/ddy184. View

Layton A, Schaller M, Homey B, Hofmann M, Bewley A, Lehmann P . Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. J Eur Acad Dermatol Venereol. 2015; 29(12):2405-10. PMC: 5054962. DOI: 10.1111/jdv.13305. View

Yamasaki K, Gallo R . Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011; 15(1):12-5. DOI: 10.1038/jidsymp.2011.4. View

Nobeyama Y, Aihara Y, Asahina A . Real-world Evidence for the Treatment of Rosacea with Sulfur or Metronidazole Preparation in Japanese Patients. JMA J. 2023; 6(4):448-454. PMC: 10628168. DOI: 10.31662/jmaj.2023-0100. View

10.

Logger J, Olydam J, Driessen R . Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020; 83(4):1088-1097. DOI: 10.1016/j.jaad.2020.04.129. View

11.

Sapadin A, Fleischmajer R . Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54(2):258-65. DOI: 10.1016/j.jaad.2005.10.004. View

12.

Sharma A, Kroumpouzos G, Kassir M, Galadari H, Goren A, Grabbe S . Rosacea management: A comprehensive review. J Cosmet Dermatol. 2022; 21(5):1895-1904. DOI: 10.1111/jocd.14816. View

13.

Rubinchik E, Dugourd D, Algara T, Pasetka C, Friedland H . Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009; 34(5):457-61. DOI: 10.1016/j.ijantimicag.2009.05.003. View

14.

Lazaridou E, Giannopoulou C, Fotiadou C, Vakirlis E, Trigoni A, Ioannides D . The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges. 2010; 9(1):21-5. DOI: 10.1111/j.1610-0387.2010.07513.x. View

15.

Xiao W, Chen M, Wang B, Huang Y, Zhao Z, Deng Z . Efficacy and safety of antibiotic agents in the treatment of rosacea: a systemic network meta-analysis. Front Pharmacol. 2023; 14:1169916. PMC: 10210163. DOI: 10.3389/fphar.2023.1169916. View

16.

Seiffert K, Ding W, Wagner J, Granstein R . ATPgammaS enhances the production of inflammatory mediators by a human dermal endothelial cell line via purinergic receptor signaling. J Invest Dermatol. 2006; 126(5):1017-27. DOI: 10.1038/sj.jid.5700135. View

17.

MacLean M . Pulmonary hypertension, anorexigens and 5-HT: pharmacological synergism in action?. Trends Pharmacol Sci. 1999; 20(12):490-5. DOI: 10.1016/s0165-6147(99)01389-9. View

18.

Choi J, Werbel T, Wang Z, Wu C, Yaksh T, Di Nardo A . Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019; 93(1):58-64. PMC: 7680644. DOI: 10.1016/j.jdermsci.2018.12.004. View

19.

Wang B, Yuan X, Huang X, Tang Y, Zhao Z, Yang B . Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: A multicenter, randomized, double-blind, double-dummy, pilot study. J Am Acad Dermatol. 2020; 84(2):543-545. DOI: 10.1016/j.jaad.2020.05.050. View

20.

Sia T, Webb T, Li S, Moskatel L, Chang A . An exploratory comparative case series of calcitonin gene-related peptide monoclonal antibodies in patients with migraine with rosacea. Br J Dermatol. 2023; 189(6):776-778. DOI: 10.1093/bjd/ljad277. View